The MDx market, will grow to $4 billion by the end of the decade, according to a market study announced today by Boston based TSG Partners, a specialty advisory group that combines corporate strategy and corporate finance.
The study covers detection of DNA variation or RNA expression with the intent to diagnose disease, determine a patient’s susceptibility to disease, or determine the prognosis of condition.
The study does not include sample preparation and revenues from contract services and testing performed on open platforms. Identification of bioterrorism agents, predisposition testing, and testing for disease presence and progression such as HPV, other emerging infectious diseases, cancer, and sepsis will drive the market in the next 3-5 years.
While no one can predict the future, diagnostic tests accompanying drugs, the so called “companion diagnostics”, will become more prevalent as pharmaceutical companies move to embrace pharmacogenomics.